In a significant month for the pharmaceutical industry and metabolic medicine, the U.S. Food and Drug Administration (FDA) has issued two landmark approvals that promise to reshape the treatment paradigms for pediatric type 1 diabetes and severe hypertriglyceridemia. On June 13, Sanofi received accelerated approval for Tzield (teplizumab-mzwv) to delay the decline of insulin production in children with stage 3 type 1 diabetes (T1D), followed shortly by the June 24 approval of Ionis Pharmaceuticals’ TRYNGOLZA (olezarsen) as the first and only treatment specifically indicated to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. These decisions reflect a growing regulatory emphasis on disease-modifying therapies and treatments targeting high-risk patient populations with limited previous options.
Advancing Pediatric Care in Type 1 Diabetes: The Tzield Expansion
The FDA’s decision to grant accelerated approval to Sanofi’s Tzield marks a pivotal shift in how clinicians approach the early stages of clinical type 1 diabetes. This new indication specifically targets children aged eight to 17 years who have been recently diagnosed with stage 3 T1D. The primary goal of the therapy in this population is to delay the decline of endogenous insulin production—measured by the body’s ability to produce its own insulin—rather than merely managing blood glucose levels with external insulin.
Type 1 diabetes is categorized into three distinct stages. Stage 1 is characterized by the presence of two or more islet autoantibodies with normal blood sugar levels. Stage 2 involves the continued presence of autoantibodies and the onset of dysglycemia (abnormal blood sugar) but remains asymptomatic. Stage 3 is the point of clinical diagnosis, where symptoms such as excessive thirst, frequent urination, and weight loss typically emerge due to the significant destruction of insulin-producing beta cells.
Clinical Data and the PROTECT Study
The approval of Tzield for stage 3 pediatric patients was heavily supported by data from the PROTECT Phase 3 clinical trial. This study focused on beta-cell function, utilizing mean C-peptide levels as a primary biomarker. C-peptide is produced in equal amounts to insulin; therefore, measuring it provides a reliable proxy for how much insulin a patient’s pancreas is still capable of secreting.
In the PROTECT trial, researchers observed that Tzield significantly slowed the decrease in C-peptide levels compared to a placebo. The assessment was conducted using a four-hour mixed-meal tolerance test, which measures the body’s insulin response to food. The difference in least-squares means was 0.13 pmol/mL (95% CI: 0.09-0.17; p<0.001) at the conclusion of the trial. This data suggests that Tzield can effectively preserve a portion of the patient’s own insulin-producing capacity for a longer period, which is critical for long-term glycemic control and the reduction of complications.
The broader clinical development program for Tzield included over 900 patients, providing a robust safety and efficacy database. While the results were positive, the FDA noted that Tzield is not effective as a disease-modifying therapy for non-autoimmune forms of diabetes.
Safety Profile and Monitoring
As a monoclonal antibody that modifies the immune system, Tzield carries specific safety considerations. The most common adverse reactions reported in the PROTECT study included lymphopenia (low white blood cell count), vomiting, rash, leukopenia, diarrhea, neutropenia, and headache. More serious risks involve cytokine release syndrome (CRS) and the potential for viral reactivation. Because Tzield influences T-cell responses, patients who are already immunocompromised face a higher risk of life-threatening viral events. Consequently, the FDA and Sanofi have emphasized the need for careful patient screening and monitoring during the treatment course.
Regulatory Context and Future Requirements
Tzield’s current status is an "accelerated approval," a pathway the FDA uses for drugs treating serious conditions that fill an unmet medical need based on a surrogate endpoint—in this case, C-peptide levels. To maintain this approval, Sanofi must verify the clinical benefit through confirmatory studies. To this end, the BETA-PRESERVE Phase 3 study has been initiated and is currently enrolling participants to provide the long-term data required for full regulatory standing.
This expansion follows a history of regulatory successes for the drug. It was previously designated as a "Breakthrough Therapy" and granted "Orphan Drug" status. Beyond the U.S., the medication is approved or under review in various jurisdictions, including the EU (under the name Teizeild), the UK, China, and Australia, reflecting a global interest in preserving beta-cell function.
Addressing Severe Hypertriglyceridemia: The Launch of TRYNGOLZA
Following the Sanofi announcement, Ionis Pharmaceuticals secured FDA approval for TRYNGOLZA (olezarsen), a monthly self-administered injection designed for adults with severe hypertriglyceridemia (sHTG). Defined by triglyceride levels equal to or greater than 500 mg/dL, sHTG is a dangerous metabolic condition that puts patients at a high risk for acute pancreatitis—a painful and potentially fatal inflammation of the pancreas.
For many patients with sHTG, traditional lipid-lowering therapies and strict dietary changes are insufficient to bring triglyceride levels below the critical 500 mg/dL threshold. TRYNGOLZA represents a mechanical breakthrough, utilizing antisense technology to inhibit the production of apolipoprotein C-III (apoC-III), a protein that regulates triglyceride metabolism in the blood.
Breakthrough Results from CORE and CORE2 Trials
The FDA’s approval of TRYNGOLZA was predicated on the results of the Phase 3 CORE and CORE2 studies, which were published in The New England Journal of Medicine. These trials demonstrated that the drug could achieve rapid and sustained reductions in triglyceride levels.
At the six-month mark, patients receiving TRYNGOLZA saw fasting triglyceride levels drop by up to 72% compared to those on a placebo. These reductions were maintained through 12 months of treatment. Perhaps more significantly, the drug reduced the incidence of acute pancreatitis events by a staggering 91%.
The clinical impact is further highlighted by the "number needed to treat" (NNT). To prevent one episode of acute pancreatitis over a year, the NNT was 20 for the general sHTG cohort. However, for high-risk patients—those with triglycerides above 880 mg/dL and a prior history of pancreatitis—the NNT dropped to four, indicating an exceptionally high level of efficacy for the most vulnerable patients. By the end of the 12-month study, 86% of treated patients had successfully lowered their triglycerides below the 500 mg/dL danger zone.
Safety and Patient Accessibility
The safety profile of TRYNGOLZA was characterized as favorable during the clinical trials. The most frequent side effects were injection site reactions and mild increases in liver enzymes, which were generally manageable.
Recognizing the challenges of managing a chronic condition like sHTG, Ionis Pharmaceuticals has launched "Ionis Every Step," a comprehensive support program. This initiative provides patients with injection training, nutritional guidance, and financial assistance to ensure that the cost of the specialty medication does not become a barrier to treatment. The drug is expected to be commercially available in the United States by July.
Broader Implications for the Healthcare Landscape
The dual approval of Tzield and TRYNGOLZA underscores a significant trend in modern medicine: the move toward precision biologics that target the underlying drivers of disease rather than just the symptoms.
Shifting the T1D Paradigm
For type 1 diabetes, the approval of Tzield for stage 3 patients represents a transition from "reactive" to "proactive" care. Historically, a T1D diagnosis was followed immediately by lifelong insulin dependence. By intervening with Tzield at the point of diagnosis, healthcare providers can potentially extend the "honeymoon phase" of the disease, where the body still produces some insulin. This can lead to easier glucose management, fewer episodes of hypoglycemia, and a lower risk of long-term vascular complications.
Redefining Lipid Management
For the cardiovascular and GI communities, TRYNGOLZA offers a solution to a long-standing gap in care. While statins and fibrates have long been the backbone of lipid management, they often fail in cases of extreme triglyceride elevation. The 91% reduction in pancreatitis events seen with olezarsen is a transformative statistic that could significantly reduce the burden on hospital emergency rooms and intensive care units, where acute pancreatitis cases are frequently treated.
Economic and Global Reach
The commercial trajectory of these drugs also highlights the high stakes of metabolic pharmaceutical development. Sanofi’s aggressive pursuit of Tzield indications follows its multi-billion-dollar acquisition of Provention Bio, signaling a major bet on the future of autoimmune diabetes treatments. Similarly, Ionis’s launch of TRYNGOLZA as an independent product marks its evolution from a research-focused biotech into a fully integrated pharmaceutical entity.
As both companies move forward with confirmatory trials and global rollouts, the medical community will be watching closely to see how these therapies perform in real-world settings. For now, the approvals offer a new sense of hope for thousands of families navigating the complexities of stage 3 type 1 diabetes and the constant threat of severe hypertriglyceridemia.
